STATEMENT OF INVESTMENTS BNY Mellon Appreciation Fund, Inc. September 30, 2024 (Unaudited)

Description	Shares	Value (\$)
Common Stocks - 99.7%		
Capital Goods - 2.4%		
BAE Systems PLC	2,701,565	44,696,734
Otis Worldwide Corp.	92,450	9,609,253
		54,305,987
Commercial & Professional Services - 1.4%		
Automatic Data Processing, Inc.	65,710	18,183,928
Verisk Analytics, Inc.	51,500	13,799,940
		31,983,868
Consumer Discretionary Distribution & Retail - 5.8%		
Amazon.com, Inc.	650,590°	121,224,435
The Home Depot, Inc.	30,000	12,156,000
		133,380,435
Consumer Durables & Apparel - 3.8%	0.205	20 (14 027
Hermes International SCA	8,395	20,614,837
LVMH Moet Hennessy Louis Vuitton SE	60,560	46,413,413 20,756,762
NIKE, Inc., Cl. B	234,805	
Consumer Services - 2.7%		87,785,012
Marriott International, Inc., Cl. A	93,690	23,291,334
McDonald's Corp.	126,735	38,592,075
Meboliaid 3 doi pi	120,733	61,883,409
Energy - 4.2%		01,000,100
Chevron Corp.	400,910	59,042,016
Exxon Mobil Corp.	313,525	36,751,401
		95,793,417
Financial Services - 15.4%		
Berkshire Hathaway, Inc., Cl. A	70 a	48,382,600
BlackRock, Inc.	60,220	57,179,492
CME Group, Inc.	122,000	26,919,300
Intercontinental Exchange, Inc.	239,215	38,427,498
Mastercard, Inc., Cl. A	76,680	37,864,584
S&P Global, Inc.	121,792	62,920,183
Visa, Inc., Cl. A	301,395 ^b	82,868,555
		354,562,212
Food, Beverage & Tobacco - 2.5%		
PepsiCo, Inc.	188,920	32,125,846
The Coca-Cola Company	366,340	26,325,192
		58,451,038
Health Care Equipment & Services - 7.0%		
Abbott Laboratories	304,440	34,709,204
Intuitive Surgical, Inc.	89,410 a	43,924,451
UnitedHealth Group, Inc.	139,925	81,811,349
		160,445,004

Description		Shares	Value (\$)
Common Stocks - 99.7% (continued)		Silates	value (\$)
Household & Personal Products6%			
The Procter & Gamble Company		77,720	13,461,104
Insurance - 2.3%		, , 20	10,101,101
The Progressive Corp.		211,640	53,705,766
Materials - 1.4%		,	,,.
The Sherwin-Williams Company		83,970	32,048,830
Media & Entertainment - 4.1%			,, ,,
Alphabet, Inc., Cl. C		571,815	95,601,750
Pharmaceuticals, Biotechnology & Life Sciences - 7.6%		,	, ,
AstraZeneca PLC, ADR		355,000	27,658,050
Eli Lilly & Co.		25,000	22,148,500
ICON PLC		10,000 a	2,873,100
Novo Nordisk A/S, ADR		833,380	99,230,557
Zoetis, Inc.		117,610	22,978,642
		·	174,888,849
Real Estate Management & Development - 1.0%			
CoStar Group, Inc.		318,040 a	23,992,938
Semiconductors & Semiconductor Equipment - 10.6%			
ASML Holding NV		78,790	65,651,767
NVIDIA Corp.		535,000	64,970,400
Taiwan Semiconductor Manufacturing Co. Ltd., ADR		210,500	36,557,535
Texas Instruments, Inc.		369,015	76,227,429
			243,407,131
Software & Services - 15.5%			
Adobe, Inc.		73,295 a	37,950,685
Gartner, Inc.		29,495 a	14,946,886
Intuit, Inc.		82,465	51,210,765
Microsoft Corp.		492,895	212,092,718
ServiceNow, Inc.		44,650 a	39,934,513
			356,135,567
Technology Hardware & Equipment - 7.8%			
Apple, Inc.		768,605	179,084,965
Transportation - 3.6%			
Canadian Pacific Kansas City Ltd.		369,795	31,632,264
Old Dominion Freight Line, Inc.		100,000	19,864,000
Union Pacific Corp.		126,310	31,132,889
			82,629,153
Total Common Stocks (cost \$797,740,163)			2,293,546,435
	1-Day		
	Yield (%)		
Investment Companies4%			
Registered Investment Companies4%			
Dreyfus Institutional Preferred Government Plus			
Money Market Fund, Institutional Shares	4.95	8,830,332°	0 020 222
(cost \$8,830,332)	4.70	· · · · · ·	8,830,332
Total Investments (cost \$806,570,495)		100.1%	2,302,376,767

Liabilities, Less Cash and Receivables	(.1%)	(1,683,865)
Net Assets	100.0%	2,300,692,902

ADR—American Depositary Receipt

^a Non-income producing security.

Security, or portion thereof, on loan. At September 30, 2024, the value of the fund's securities on loan was \$16,792,846 and the value of the collateral was \$17,148,179, consisting of U.S. Government & Agency securities. In addition, the value of collateral may include pending sales that are also on loan.

Investment in affiliated issuer. The investment objective of this investment company is publicly available and can be found within the investment company's prospectus. See notes to financial statements.